MBAI Stock Summary and Trading Ideas (Check-Cap Ltd. - Ordinary Share | NASDAQ:MBAI)

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Check-Cap Ltd. - Ordinary Share trades on the NASDAQ stock market under the symbol MBAI.

As of April 17, 2026, MBAI stock price climbed to $1.88 with 92,429 million shares trading.

MBAI has a beta of -0.62, meaning it tends to be less sensitive to market movements. MBAI has a correlation of 0.02 to the broad based SPY ETF.

MBAI has a market cap of $13.70 million. This is considered a Sub-Micro Cap stock.

MBAI support price is $1.73 and resistance is $1.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBAI shares will trade within this expected range on the day.